INTRODUCTION: Polymorphisms in the beta-2-adrenergic receptor (ADRB2) gene have been studied in relation to risk of type 2 diabetes and obesity, risk factors that have received increased attention in relation to breast cancer. We evaluated the hypothesis that ADRB2 variants (rs1042713, rs1042714) are associated with breast cancer risk in non-Hispanic white (NHW) and Hispanic (H) women using data from a population-based case-control study conducted in the southwestern United States. METHODS: Data on lifestyle and medical history, and blood samples, were collected during in-person interviews for incident primary breast cancer cases (1,244 NHW, 606 H) and controls (1,330 NHW, 728 H). ADRB2 genotypes for rs1042713(G/A) and rs1042714(G/C) were determined using TaqMan assays. The associations of each variant and corresponding haplotypes with breast cancer were estimated using multivariable logistic regression. RESULTS: Two copies compared to one or zero copies of the ADRB2 G-G haplotype were associated with increased breast cancer risk for NHW women [odds ratio (OR), 1.95; 95 % confidence interval (95 % CI), 1.26-3.01], but with reduced risk for H women [OR, 0.74; 95 % CI, 0.50-1.09]. Effect estimates were strengthened for women with a body mass index (BMI) ≥25 kg/m(2) [H: OR, 0.50; 95 % CI, 0.31-0.82; NHW: OR, 3.85; 95 % CI, 1.88-7.88] and for H women with a history of diabetes [H: OR, 0.32; 95 % CI, 0.12-0.89]. CONCLUSIONS: These data suggest that ethnicity modifies the association between the ADRB2 G-G haplotype and breast cancer risk, and being overweight or obese enhances the divergence of risk between H and NHW women.
INTRODUCTION: Polymorphisms in the beta-2-adrenergic receptor (ADRB2) gene have been studied in relation to risk of type 2 diabetes and obesity, risk factors that have received increased attention in relation to breast cancer. We evaluated the hypothesis that ADRB2 variants (rs1042713, rs1042714) are associated with breast cancer risk in non-Hispanic white (NHW) and Hispanic (H) women using data from a population-based case-control study conducted in the southwestern United States. METHODS: Data on lifestyle and medical history, and blood samples, were collected during in-person interviews for incident primary breast cancer cases (1,244 NHW, 606 H) and controls (1,330 NHW, 728 H). ADRB2 genotypes for rs1042713(G/A) and rs1042714(G/C) were determined using TaqMan assays. The associations of each variant and corresponding haplotypes with breast cancer were estimated using multivariable logistic regression. RESULTS: Two copies compared to one or zero copies of the ADRB2 G-G haplotype were associated with increased breast cancer risk for NHW women [odds ratio (OR), 1.95; 95 % confidence interval (95 % CI), 1.26-3.01], but with reduced risk for H women [OR, 0.74; 95 % CI, 0.50-1.09]. Effect estimates were strengthened for women with a body mass index (BMI) ≥25 kg/m(2) [H: OR, 0.50; 95 % CI, 0.31-0.82; NHW: OR, 3.85; 95 % CI, 1.88-7.88] and for H women with a history of diabetes [H: OR, 0.32; 95 % CI, 0.12-0.89]. CONCLUSIONS: These data suggest that ethnicity modifies the association between the ADRB2 G-G haplotype and breast cancer risk, and being overweight or obese enhances the divergence of risk between H and NHW women.
Authors: Dmitri V Zaykin; Peter H Westfall; S Stanley Young; Maha A Karnoub; Michael J Wagner; Margaret G Ehm Journal: Hum Hered Date: 2002 Impact factor: 0.444
Authors: Lisa M Hines; Betsy Risendal; Martha L Slattery; Kathy B Baumgartner; Anna R Giuliano; Carol Sweeney; Dana E Rollison; Tim Byers Journal: Cancer Date: 2010-07-01 Impact factor: 6.860
Authors: Libby M Morimoto; Emily White; Z Chen; Rowan T Chlebowski; Jennifer Hays; Lewis Kuller; Ana Marie Lopez; JoAnn Manson; Karen L Margolis; Paola C Muti; Marcia L Stefanick; Anne McTiernan Journal: Cancer Causes Control Date: 2002-10 Impact factor: 2.506
Authors: Martha L Slattery; Kathy B Baumgartner; Anna R Giuliano; Tim Byers; Jennifer S Herrick; Roger K Wolff Journal: Breast Cancer Res Treat Date: 2011-04-08 Impact factor: 4.872
Authors: Augusto A Litonjua; Li Gong; Qing Ling Duan; Jaekyu Shin; Mariellen J Moore; Scott T Weiss; Julie A Johnson; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2010-01 Impact factor: 2.089
Authors: Avonne E Connor; Kathy B Baumgartner; Richard N Baumgartner; Christina M Pinkston; Stephanie D Boone; Esther M John; Gabriela Torres-Mejía; Lisa M Hines; Anna R Giuliano; Roger K Wolff; Martha L Slattery Journal: J Womens Health (Larchmt) Date: 2015-12-18 Impact factor: 2.681
Authors: Filipa Lynce; Kristi D Graves; Lina Jandorf; Charite Ricker; Eida Castro; Laura Moreno; Bianca Augusto; Laura Fejerman; Susan T Vadaparampil Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: Alexander Kondrashov; Nurul A N Mohd Yusof; Alveera Hasan; Joëlle Goulding; Thusharika Kodagoda; Duc M Hoang; Nguyen T N Vo; Tony Melarangi; Nazanin Dolatshad; Julia Gorelik; Stephen J Hill; Sian E Harding; Chris Denning Journal: Mol Ther Methods Clin Dev Date: 2020-10-27 Impact factor: 6.698